OrganoTherapeutics

Established in 2019 in Luxembourg, OrganoTherapeutics has made a remarkable contribution to the development of the biotech area. It also has received sponsorship in one round which took place in 2020, with its most recent investors being Canada-based Creative Destruction Lab (CDL) and U.S.-based startup accelerator MassChallenge.

During the operation period, OrganoTherapeutics has effectively used cutting-edge human-specific mini-brains to discover and develop a variety of valuable drug candidates targeting Parkinson’s disease. Besides that, it also screens new molecules on its proprietary human-specific mini-brains. These represent a model mimicking faithfully the human Parkinson’s disease pathology. Apparently, OrganoTherapeutics aims at developing new drug candidates against Parkinson’s disease which are tested in state-of-the-art 3D patient models. OrganoTherapeutics has made progress in its first own proprietary drug candidates and has access to attractive libraries for further screening.

Other than that, OrganoTherapeutics has created human-specific mini-brains, which depict the pathology of the disease in order to identify drug targets and develop candidates for the treatment of Parkinson’s disease. With a view to changing animal experiments in drug development as much as possible, the biotech’s midbrain organoids are engendered from somatic cell samples that are obtained from healthy individuals and Parkinson’s patients.

Founded: 2019

Headquarters: Luxembourg City, Luxembourg

Website: http://organo-therapeutics.com/